Philipp E. Bartko

260 posts

Philipp E. Bartko banner
Philipp E. Bartko

Philipp E. Bartko

@pe_bartko

Physician and researcher focused on structural heart disease, valvular driven heart failure, structural heart interventions.

Vienna, Austria Katılım Aralık 2018
2K Takip Edilen1.7K Takipçiler
Philipp E. Bartko retweetledi
Philippe Pibarot
Philippe Pibarot@PPibarot·
In Low Gradient AS, reduced GLS, increased ECV and LGE on CMR was associated with worse outcomes. Comprehensive myocardial characterization using cardiac magnetic resonance associates with outcomes in low gradient severe aortic stenosis academic.oup.com/ehjcimaging/ad…
Philippe Pibarot tweet media
English
3
30
87
0
Philipp E. Bartko retweetledi
João Cavalcante
João Cavalcante@JoaoLCavalcante·
New multicenter TOPAS CMR study led by @Miho_Fukui_ and @PPibarot demonstrates the importance of phenotyping myocardial structural and function using #whyCMR in the complex group of low-gradient AS. Prognosis worsens with greater # of CMR risk markers. bit.ly/3yZGBr3
João Cavalcante tweet media
English
5
56
119
0
Philipp E. Bartko retweetledi
PCRonline 🫀
PCRonline 🫀@PCRonline·
Join @EdwardsLifesci in Paris or online for their #EuroPCR 2022 symposiums: ➡️"Valve in Valve and the journey starting with the first prosthesis" with @ValveDisease on May 17th ➡️"Learnings from an optimised #TAVI patient's journey" on May 18th Sponsored post by @EdwardsLifesci
English
1
3
14
0
Philipp E. Bartko retweetledi
Akihisa Kataoka, MD, PhD, FESC
Excited to announce that my new provocative maneuver to detect PFO using party balloon during Saline Contrast Transthoracic Echocardiography has been published in JACC: Case Reports. jacc.org/doi/10.1016/j.…
English
1
19
86
0
Philipp E. Bartko retweetledi
Giuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai@gbiondizoccai·
"Unsupervised clustering supports the association of sMR with mortality predominantly driven by the small LV cavity phenotype, as previously suggested by a conceptional framework and termed disproportionate sMR" jacc.org/doi/10.1016/j.…
Giuseppe Biondi-Zoccai tweet media
English
0
2
8
0
Philipp E. Bartko retweetledi
CardioTomLuscher
CardioTomLuscher@TomLuscher·
Ever thought of preventing aortic stenosis (AS) instead having AVR or TAVI? Molecular mechanisms are unravelled and we will prevent AS like CAD. Statins do not work, but Lp(a) is a target in some, in others molecular mechanisms are deciphered - read it in the EHJ online!
CardioTomLuscher tweet media
English
2
58
171
0
Philipp E. Bartko retweetledi
David Ouyang, MD
David Ouyang, MD@David_Ouyang·
In anticipation of #ASE21 this weekend, we'd like to share this AI on #EchoFirst. This frame-to-frame measurement of PLAX was fully automated by EchoNet-LVH. More examples and preprint soon! @ASE360 @CedarsSinai
English
13
69
297
0
Philipp E. Bartko retweetledi
The Lancet
The Lancet@TheLancet·
Each 5mmHg reduction in systolic blood pressure lowered the relative risk of cardiovascular events by around 10%. Authors, @kazemr et al, call for changes to global guidelines. hubs.li/H0MhDYV0 2/2
The Lancet tweet mediaThe Lancet tweet media
English
1
24
44
0
Philipp E. Bartko retweetledi
Philipp E. Bartko retweetledi
Carlos G Santos-Gallego, MD
Carlos G Santos-Gallego, MD@SantosGallegoMD·
So proud to have lectured today at #ESCCongress about SGLT2i! Thanks for the invitation, @escardio! Session: Meet the Experts: fuel up! – targeting cardiac energy metabolism in type 2 diabetes and HF… Title: ... By Pharmacological Interventions: SGLT2i in heart failure
Carlos G Santos-Gallego, MD tweet mediaCarlos G Santos-Gallego, MD tweet mediaCarlos G Santos-Gallego, MD tweet mediaCarlos G Santos-Gallego, MD tweet media
English
10
19
80
0